Heterocyclylamines as PI3K Inhibitors
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 8 of these applications claim priority to application 13/601,349, filed Aug 31, 2012. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,707,233 | Heterocyclylamines as PI3K Inhibitors In force · Low confidence UsedRemaining | Incyte Holdings Corporation | In force | Low confidence | ||
| US 9,730,939 | Heterocyclylamines as PI3K Inhibitors In force · Low confidence | Incyte Holdings Corporation | In force | Low confidence | ||
| US 10,092,570 | Heterocyclylamines as PI3K Inhibitors In force · Medium confidence | Incyte Holdings Corporation | In force | Medium confidence | ||
| US 10,376,513 | Heterocyclylamines as PI3K Inhibitors In force · Low confidence | Incyte Holdings Corporation | In force | Low confidence | ||
| US 10,646,492 | Heterocyclylamines as PI3K Inhibitors In force · High confidence | Incyte Holdings Corporation | In force | High confidence | ||
| US 11,433,071 | Heterocyclylamines as PI3K Inhibitors In force · Low confidence | Incyte Holdings Corporation | In force | Low confidence | ||
| US 11,819,505 | Heterocyclylamines as PI3K Inhibitors In force · Low confidence | Incyte Holdings Corporation | In force | Low confidence | ||
| US 12,201,636 | Heterocyclylamines as PI3K Inhibitors In force · Medium confidence | Incyte Corporation | In force | Medium confidence | ||
| US 9,199,982 | Heterocyclylamines as PI3K Inhibitors In force · High confidence | Incyte Holdings Corporation and Incyte Corporation | In force | High confidence | ||
| Application 18/962,341 | Heterocyclylamines as PI3K Inhibitors Pending Not granted | Incyte Corporation | Pending | Not granted |
10 of 10 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
8 of these are in force and held by Incyte Corporation.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.